×
S&P 500   3,751.52 (-1.93%)
DOW   30,432.92 (-2.14%)
QQQ   279.58 (-0.90%)
AAPL   138.66 (-0.19%)
MSFT   256.65 (-1.13%)
META   161.22 (+0.74%)
GOOGL   2,165.24 (-0.44%)
AMZN   110.43 (+0.79%)
TSLA   665.23 (-2.43%)
NVDA   145.84 (+0.42%)
NIO   21.54 (+0.84%)
BABA   115.36 (-0.55%)
AMD   73.55 (-0.16%)
MU   54.97 (+2.46%)
CGC   2.66 (-5.34%)
T   20.94 (-1.74%)
GE   60.83 (-4.27%)
F   10.90 (-3.71%)
DIS   94.10 (-2.12%)
AMC   12.94 (-4.36%)
PFE   50.60 (-3.27%)
PYPL   72.00 (+0.84%)
NFLX   178.84 (-0.62%)
S&P 500   3,751.52 (-1.93%)
DOW   30,432.92 (-2.14%)
QQQ   279.58 (-0.90%)
AAPL   138.66 (-0.19%)
MSFT   256.65 (-1.13%)
META   161.22 (+0.74%)
GOOGL   2,165.24 (-0.44%)
AMZN   110.43 (+0.79%)
TSLA   665.23 (-2.43%)
NVDA   145.84 (+0.42%)
NIO   21.54 (+0.84%)
BABA   115.36 (-0.55%)
AMD   73.55 (-0.16%)
MU   54.97 (+2.46%)
CGC   2.66 (-5.34%)
T   20.94 (-1.74%)
GE   60.83 (-4.27%)
F   10.90 (-3.71%)
DIS   94.10 (-2.12%)
AMC   12.94 (-4.36%)
PFE   50.60 (-3.27%)
PYPL   72.00 (+0.84%)
NFLX   178.84 (-0.62%)
S&P 500   3,751.52 (-1.93%)
DOW   30,432.92 (-2.14%)
QQQ   279.58 (-0.90%)
AAPL   138.66 (-0.19%)
MSFT   256.65 (-1.13%)
META   161.22 (+0.74%)
GOOGL   2,165.24 (-0.44%)
AMZN   110.43 (+0.79%)
TSLA   665.23 (-2.43%)
NVDA   145.84 (+0.42%)
NIO   21.54 (+0.84%)
BABA   115.36 (-0.55%)
AMD   73.55 (-0.16%)
MU   54.97 (+2.46%)
CGC   2.66 (-5.34%)
T   20.94 (-1.74%)
GE   60.83 (-4.27%)
F   10.90 (-3.71%)
DIS   94.10 (-2.12%)
AMC   12.94 (-4.36%)
PFE   50.60 (-3.27%)
PYPL   72.00 (+0.84%)
NFLX   178.84 (-0.62%)
S&P 500   3,751.52 (-1.93%)
DOW   30,432.92 (-2.14%)
QQQ   279.58 (-0.90%)
AAPL   138.66 (-0.19%)
MSFT   256.65 (-1.13%)
META   161.22 (+0.74%)
GOOGL   2,165.24 (-0.44%)
AMZN   110.43 (+0.79%)
TSLA   665.23 (-2.43%)
NVDA   145.84 (+0.42%)
NIO   21.54 (+0.84%)
BABA   115.36 (-0.55%)
AMD   73.55 (-0.16%)
MU   54.97 (+2.46%)
CGC   2.66 (-5.34%)
T   20.94 (-1.74%)
GE   60.83 (-4.27%)
F   10.90 (-3.71%)
DIS   94.10 (-2.12%)
AMC   12.94 (-4.36%)
PFE   50.60 (-3.27%)
PYPL   72.00 (+0.84%)
NFLX   178.84 (-0.62%)
NASDAQ:ANGN

Angion Biomedica Stock Forecast, Price & News

$1.10
-0.02 (-1.79%)
(As of 07/5/2022 10:48 AM ET)
Add
Compare
Today's Range
$1.10
$1.12
50-Day Range
$1.10
$2.02
52-Week Range
$1.03
$14.18
Volume
5,536 shs
Average Volume
304,010 shs
Market Capitalization
$32.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Angion Biomedica MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
1,431.5% Upside
$17.00 Price Target
Short Interest
Healthy
4.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
-0.01mentions of Angion Biomedica in the last 14 days
Based on 15 Articles This Week
Insider Trading
Acquiring Shares
$109,949 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.87) to ($1.82) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.19 out of 5 stars

Medical Sector

195th out of 1,428 stocks

Pharmaceutical Preparations Industry

86th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Angion Biomedica logo

About Angion Biomedica (NASDAQ:ANGN) Stock

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

ANGN Stock News Headlines

Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush."
Experts predict that the global lithium market will balloon by 500%. That's wonderful news for investors, because a "sure-thing" like this appears once in a lifetime. And this small-cap company just snagged what could be one of the world's largest lithium deposits.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush."
Experts predict that the global lithium market will balloon by 500%. That's wonderful news for investors, because a "sure-thing" like this appears once in a lifetime. And this small-cap company just snagged what could be one of the world's largest lithium deposits.
Angion Biomedica Corp. Common Stock (ANGN)
Thursday 12/30 Insider Buying Report: ANGN, PLL
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANGN
Fax
N/A
Employees
72
Year Founded
N/A

Company Calendar

Last Earnings
5/16/2022
Today
7/05/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+3,627.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33333333333333
Research Coverage
3 Analysts

Profitability

Net Income
$-54,570,000.00
Net Margins
-108.57%
Pretax Margin
-108.57%

Debt

Sales & Book Value

Annual Sales
$28.31 million
Book Value
$2.72 per share

Miscellaneous

Free Float
24,057,000
Market Cap
$32.96 million
Optionable
Not Optionable
Beta
0.82














Angion Biomedica Frequently Asked Questions

Should I buy or sell Angion Biomedica stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Angion Biomedica in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Angion Biomedica stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANGN, but not buy additional shares or sell existing shares.
View analyst ratings for Angion Biomedica
or view top-rated stocks.

What is Angion Biomedica's stock price forecast for 2022?

3 Wall Street analysts have issued twelve-month price objectives for Angion Biomedica's stock. Their ANGN stock forecasts range from $8.00 to $28.00. On average, they expect Angion Biomedica's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,417.9% from the stock's current price.
View analysts' price targets for Angion Biomedica
or view top-rated stocks among Wall Street analysts.

How has Angion Biomedica's stock performed in 2022?

Angion Biomedica's stock was trading at $2.90 on January 1st, 2022. Since then, ANGN shares have decreased by 61.4% and is now trading at $1.12.
View the best growth stocks for 2022 here
.

When is Angion Biomedica's next earnings date?

Angion Biomedica is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Angion Biomedica
.

How were Angion Biomedica's earnings last quarter?

Angion Biomedica Corp. (NASDAQ:ANGN) issued its earnings results on Monday, May, 16th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.04. The business earned $1.65 million during the quarter, compared to analysts' expectations of $1.23 million. Angion Biomedica had a negative trailing twelve-month return on equity of 44.25% and a negative net margin of 108.57%.
View Angion Biomedica's earnings history
.

Who are Angion Biomedica's key executives?

Angion Biomedica's management team includes the following people:
  • Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D., Pres, CEO & Chairman (Age 50, Pay $587.1k)
  • Dr. John F. Neylan M.D., Exec. VP, Chief Medical Officer, & Head of Research (Age 69, Pay $468.65k)
  • Mr. Gregory S. Curhan, Chief Financial Officer (Age 60)
  • Ms. Jennifer J. Rhodes J.D., Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec. (Age 52) (LinkedIn Profile)
  • Mr. Daniel Iazzetti, VP of HR
  • Bruce Rich, Assistant Sec.

When did Angion Biomedica IPO?

(ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Stifel served as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

What is Angion Biomedica's stock symbol?

Angion Biomedica trades on the NASDAQ under the ticker symbol "ANGN."

How do I buy shares of Angion Biomedica?

Shares of ANGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Angion Biomedica's stock price today?

One share of ANGN stock can currently be purchased for approximately $1.12.

How much money does Angion Biomedica make?

Angion Biomedica (NASDAQ:ANGN) has a market capitalization of $33.56 million and generates $28.31 million in revenue each year. The company earns $-54,570,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Angion Biomedica have?

Angion Biomedica employs 72 workers across the globe.

How can I contact Angion Biomedica?

Angion Biomedica's mailing address is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. The official website for Angion Biomedica is www.angion.com. The company can be reached via phone at 415-655-4899 or via email at daniel@lifesciadvisors.com.

This page (NASDAQ:ANGN) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.